Tramadol is used similarly to
codeine, to treat moderate to severe pain. Pharmacologically, Tramadol is
similar to levorphanol (albeit with much lower μ-agonism), as both agents are
also NMDA-antagonists with SNRI activity. Dextropropoxyphene (Darvon) & M1-like
molecule tapentadol (Nucynta, a new synthetic atypical opioid made to mimic the
agonistic properties of tramadol's metabolite, M1(O-Desmethyltramadol)) also
have similar activities.
Tramadol is also molecularly similar to venlafaxine
(Effexor) and has similar SNRI effects, with antinociceptive effects. It has
been suggested that tramadol could be effective for alleviating symptoms of depression,
anxiety, and phobias because of its action on the noradrenergic and
serotonergic systems, such as its "atypical" opioid activity.
However, health professionals have not endorsed its use for these disorders,
claiming it may be used as a unique treatment (only when other treatments
failed), and must be used under the control of a psychiatrist.
In May 2009, the United States
Food and Drug Administration issued a Warning Letter to Johnson & Johnson,
alleging that a promotional website commissioned by the manufacturer had
"overstated the efficacy" of the drug, and "minimized the serious
risks". The company which produced it, the German pharmaceutical company
Grünenthal GmbH, were alleged to be guilty of "minimizing" the
habituating nature of the drug, although it showed little abuse liability in
preliminary tests.
The 2010 Physicians Desk Reference contains
several warnings from the manufacturer, which were not present in prior years.
The warnings include stronger language regarding the habituating potential of
tramadol, the possibility of difficulty breathing while on the medication, a
new list of more serious side effects, and a notice that tramadol is not to be
used in place of opiate medications for addicts. Tramadol is also not to be
used in efforts to wean addict patients from opiate drugs, nor to be used to
manage long-term opiate addiction.
No comments:
Post a Comment